What is Genomic Expression?
Genomic Expression is at the forefront of RNA analysis, leveraging its proprietary OneRNA platform. This innovative technology facilitates the detection of diseases, continuous health monitoring, and the design of next-generation cures. The platform's capabilities extend to repurposing existing drugs for personalized patient treatments and accelerating the development of novel RNA therapeutics. Primarily targeting healthcare professionals and patients, Genomic Expression aims to enhance treatment options, particularly within oncology. The company's strategic focus on scalability and artificial intelligence integration positions it as a key player in the evolving RNA analysis industry.
How much funding has Genomic Expression raised?
Genomic Expression has raised a total of $4.3M across 2 funding rounds:
Grant
$4.2M
Debt
$50K
Grant (2018): $4.2M, investors not publicly disclosed
Debt (2021): $50K led by PPP
What's next for Genomic Expression?
With the recent substantial expansion capital, Genomic Expression is poised for significant growth and further development of its OneRNA platform. The enterprise-level funding context suggests a strategic push towards scaling operations, enhancing AI capabilities, and potentially expanding clinical trials or market reach. This investment will likely fuel advancements in disease detection and the creation of novel RNA therapeutics, solidifying the company's role in personalized medicine and advanced cancer care.
See full Genomic Expression company page
